Results 11 to 20 of about 59,185 (303)

Molecular Aspects of Varicella-Zoster Virus Latency [PDF]

Annals of Internal Medicine, 2018
Primary varicella-zoster virus (VZV) infection causes varicella (chickenpox) and the establishment of a lifelong latent infection in ganglionic neurons. VZV reactivates in about one-third of infected individuals to cause herpes zoster, often accompanied ...
Depledge, D.P. (Daniel P.), Ouwendijk, W.J.D. (Werner), Sadaoka, T. (Tomohiko)   +2 more
core   +9 more sources

Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study [PDF]

Human Vaccines & Immunotherapeutics
Insufficient coverage of herpes zoster vaccination is a challenge faced by China. This study explores herpes zoster vaccination coverage, willingness, and their predictive factors among individuals aged 50 and above in Ningbo City, aiming to formulate ...
Yingying Zhu, Zhenbo Tao, Hongwei Feng, Qianqian Xu, Lingwei Chen, Shige Ding, Yuhong Li, Ying Dong   +7 more
doaj   +2 more sources

Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project

BMC Infectious Diseases
Background Herpes Zoster is an age dependent disease and as such it represents a problem in the Italian social context, where the demographic curve is characterized by an overrepresentation of the elderly population.
Aurelia Salussolia, Angelo Capodici, Francesca Scognamiglio, Giusy La Fauci, Giorgia Soldà, Marco Montalti, Zeno Di Valerio, Maria Pia Fantini, Anna Odone, Claudio Costantino, Heidi J. Larson, Julie Leask, Jacopo Lenzi, Davide Gori, on behalf of the OBVIOUS board   +14 more
doaj   +2 more sources

Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. [PDF]

Clin Infect Dis, 2020
The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% against HZ in healthy immunocompetent adults aged ≥50 years after vaccination.
Levin MJ, Weinberg A.
europepmc   +2 more sources

Herpes zoster vaccination. An update

Przegląd Dermatologiczny, 2022
Herpes zoster/shingles is a cutaneous condition caused by the reactivation of varicella zoster virus. The condition mostly occurs when the cell mediated immunity towards varicella zoster virus, which was developed during the varicella zoster virus ...
Khairuddin Djawad, Safruddin Amin, Anni Adriani, Widyawati Djamaluddin, Dirmawati Kadir, Sri Muchtar   +5 more
doaj   +2 more sources

Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis [PDF]

The Lancet Healthy Longevity, 2022
James Mbinta, Binh P. Nguyen, Prosper Mandela Amaltinga Awuni, Janine Paynter, Colin R Simpson   +4 more
openalex   +2 more sources

Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study. [PDF]

Lancet Reg Health West Pac, 2023
Mbinta JF, Wang AX, Nguyen BP, Paynter J, Awuni PMA, Pine R, Sporle AA, Simpson CR.   +7 more
europepmc   +2 more sources

Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster

Arthritis Research & Therapy
Background Risk of cardiovascular events may increase after herpes zoster; therefore, American College of Rheumatology guidelines strongly recommend vaccination against herpes zoster in patients aged ≥ 18 years with rheumatic and musculoskeletal diseases
Jeffrey R. Curtis, Danielle M. Conrad, Whitney S. Krueger, Andrew P. Gara, Kevin L. Winthrop   +4 more
doaj   +2 more sources

Evaluating the impact of the vaccination prescription program on herpes zoster vaccine coverage in Ningbo, China: An interrupted time series analysis. [PDF]

Hum Vaccin Immunother
Wang J, Wang J, Li N, Du D, Zhang D, Ma R.   +5 more
europepmc   +3 more sources

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy. [PDF]

Clin Transl Gastroenterol
Caldera F, Mogallapalli H, Abusalim AR, Farraye FA, Hayney MS.   +4 more
europepmc   +2 more sources